Masaki Ishikawa MD, Presenter: Nothing to Disclose

Masahiro Horikawa MD, Abstract Co-Author: Nothing to Disclose

Barry T Uchida, Abstract Co-Author: Nothing to Disclose

Hans A Timmermans, Abstract Co-Author: Nothing to Disclose

John Andrew Kaufman MD, Abstract Co-Author: Consultant, Bio2 Technologies, Inc Consultant, Cook Group Incorporated Consultant, Covidien AG Consultant, W. L. Gore & Associates, Inc Consultant, Guerbet SA Stockholder, Hatch Medical LLC Stockholder, VuMedi, Inc Stockholder, Veniti, Inc Royalties, Reed Elsevier Advisory Board, Delcath Systems, Inc Researcher, W. L. Gore & Associates, Inc Researcher, Guerbet SA

Kazuo Awai MD, Abstract Co-Author: Research Grant, Toshiba Corporation Research Grant, Hitachi Ltd Research Grant, Bayer AG Research Consultant, DAIICHI SANKYO Group Research Grant, Eisai Co, Ltd

Takuji Yamagami MD, Abstract Co-Author: Nothing to Disclose

Recently, a mixture of n-butyl cyanoacrylate, Lipiodol and ethanol at ration of 1:1:3 (NLE 113) as new embolization material was introduced. The character of this embolization material is changed because n-butyl cyanoacrylate (NBCA) polymerization can be accelerated by addition of ethanol to NBCA and Lipiodol. Controllability of embolization for AVMs remains controversial. We evaluated usability of NLE in vitro model for AVMs.

 An original simulation circuit component including an artificial nidus was constructed to generate pulsatile flow (Figure 1). This system was filled with heparinized swine blood. NBCA and Lipiodol mixtures at ratios of 1:1, 1:3, 1:5 and 1:10, and NLE 113 with flow control or without flow control was injected to achieve complete embolization. Results of embolization were classified as complete filled, proximal embolization, pass through or sift to distal after balloon deflation, and each session was compared (Figure 2).

NLE 113 with flow control was complete filled in 6/6 cases (Figure 3). NBCA and Lipiodol mixture at ration of 1:1 with flow control was complete filled in 3/6 cases. NBCA and Lipiodol mixture at ration of 1:5 without flow control was complete filled in 3/6 cases. Other sessions did not achieve complete filled embolization.

Optimal embolization control of the AVM model was best using NLE 113 with flow control.

In liquid embolic materials have difficult controllability, NLE 113 have excellent controllability under flow control. NLE 113 can be acceptable as embolic material for arteriovenous malformation.

Ishikawa, M, Horikawa, M, Uchida, B, Timmermans, H, Kaufman, J, Awai, K, Yamagami, T, A Mixture of N-Butyl Cyanoacrylate, Lipiodol and Ethanol under Flow Control Using an Arteriovenous Malformation (AVM) Model, Is It Useful for Embolization.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14016896.html